Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1

Journal of Virology

Volumn 73, Issue 5, 1999, Pages 3744-3752

  Martinez Picado, Javier ^a,b   Savara, Anu V ^a   Sutton, Lorraine ^a   D'Aquila, Richard T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b IrsiCaixa Foundation   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

NELFINAVIR; PROTEINASE INHIBITOR; SAQUINAVIR;

AMINO ACID SUBSTITUTION; ANTIGEN PRESENTATION; ARTICLE; CLONAL ANERGY; CROSS RESISTANCE; ENZYME INHIBITION; ENZYME SUBSTRATE; FITNESS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; VIRUS CHARACTERIZATION; VIRUS MUTANT; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 0032928065     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.73.5.3744-3752.1999     Document Type: Article

References (62)

1. Adachi, A., H. E. Gendelman, S. Koening, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and non-human cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
2. Back, N. K., M. Nijhuls, W. Keulen, C. A. Boucher, B. O. Oude Essink, A. B. van Kuilenburg, A. H. van Gennip, and B. Berkhout. 1996. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J. 15:4040-4049.
3. Blaak, H., M. Brouwer, L. J. Ran, F. Wolf, and H. Schuitemaker. 1998. In vitro replication kinetics of human immunodeficiency virus type 1 (HIV-1) variants in relation to virus load in long-term survivors of HIV-1 infection. J. Infect. Dis. 177:600-610.
4. Borman, A. M., S. Paulous, and F. Clavel. 1996. Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug. J. Gen. Virol. 77:419-426.
5. Boucher, C. A., R. van Leeuwen, P. Kellam, P. Schipper, J. Tijnagel, J. M. Lange, and B. A. Larder. 1993. Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 37:1525-1530.
6. Brooks, J. T., M. V. Vliet, and P. E. Sax. 1998. Viral load reduction after changing from nelfinavir-to indinavir-containing regimens and associated resistance mutations, abstract 12342. In Abstracts of the 12th World AIDS Conference.
7. Caliendo, A. M., A. Savara, D. An, K. DeVore, J. C. Kaplan, and R. T. D'Aquila. 1996. Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication. J. Virol. 70:2146-2153.
8. Chow, Y. K., M. S. Hirsch, D. P. Merrill, L. J. Bechtel, J. J. Eron, J. C. Kaplan, and R. T. D'Aquila. 1993. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature 361:650-654.
9. Coffin, J. M. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483-489.
10. Condra, J. H., D. J. Holder, W. A. Schleif, O. M. Blahy, R. M. Danovich, L. J. Gabryelsi, D. J. Graham, D. Laird, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, M. Shivaprakash, T. Yang, J. A. Chodakewitz, P. J. Deutsch, R. Y. Leavitt, F. E. Massari, J. W. Mellors, K. E. Squires, R. T. Steigbigel, H. Teppler, and E. A. Emini. 1996. Genetic correlates of in vivo viral resistance to indinavir, a HIV-1 protease inhibitor. J. Virol. 70:8270-8276.
11. Condra, J. H., W. A. Schleif, O. M. Blahy, L. J. Gabryelski, D. J. Graham, J. C. Quintero, A. Rhodes, M. Shivaprakash, D. Titus, T. Yang, H. Teppler, K. E. Squires, P. J. Deutsch, and E. A. Emini. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569-571.
12. Croteau, G., L. Doyon, D. Thibeault, G. McKercher, L. Pilote, and D. Lamarre. 1997. Impaired fitness of HIV-1 variants with high-level resistance to protease inhibitors. J Virol. 71:1089-1096.
13. D'Aquila, R. T., V. A. Johnson, S. L. Welles, A. J. Japour, D. R. Kuritzkes, V. DeGruttola, P. S. Reichelderfer, R. W. Coombs, C. S. Crumpacker, J. O. Kahn, et al. 1995. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. Ann. Intern. Med. 122:401-408.
14. Deeks, S., R. Grant, N. Horton, N. Simmonds, S. Follansbee, and S. Eastman. 1997. Virologie effect of ritonavir plus saquinavir in subjects who have failed indinavir, abstr. I-205. In Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
15. Doyon, L., G. Croteau, D. Thibeault, F. Poulin, L. Pilote, and D. Lamarre. 1996. Second locus involved in HIV-1 resistance to protease inhibitors. J. Virol. 70:3763-3769.
16. Eastman, P. S., J. Mittler, R. Kelso, C. Gee, E. Boyer, J. Kolberg, M. Urdea, J. M. Leonard, D. W. Norbeck, H. Mo, and M. Markowitz. 1998. Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy. J. Virol. 72:5154-5164.
17. Erickson-Viitanen, S., J. Manfredi, P. Viitanen, D. E. Tribe, R. Tritch, C. A. D. Hutchison, D. D. Loeb, and R. Swanstrom. 1989. Cleavage of HIV-1 gag polyprotein synthesized in vitro: sequential cleavage by the viral protease. AIDS Res. Hum. Retroviruses 5:577-591.
18. Gallant, J. E., S. Barnett, C. Raines, and C. Hall. 1998. Efficacy and durability of ritonavir/saquinavir as salvage therapy after failure of initial protease inhibitor regimen, abstr. 12330. In Abstracts of the 12th World AIDS Conference.
19. Gallant, J. E., C. Hall, S. Barnett, and C. Raines. 1998. J. E., C. Hall, S. Barnett, and C. Raines. 1998. Ritonavir/saquinavir (RTV/SQV) as salvage therapy after failure of initial protease inhibitor (Pl) regimen, abstr. 510. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections.
20. Gibbs, J. S., D. A. Regier, and R. C. Desrosiers. 1994. Construction and in vitro properties of HIV-1 mutants with deletions in "nonessential" genes. AIDS Res. Hum. Retroviruses 10:343-350.
21. Goudsmit, J., A. de Ronde, E. de Rooij, and R. de Boer. 1997. Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 sub-populations differing at reverse transcriptase codons 41 and 215. J. Virol. 71:4479-4484.
22. Goudsmit, J., A. de Ronde, D. D. Ho, and A. S. Perelson. 1996. Human immunodeficiency virus fitness in vivo: calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase. J. Virol. 70:5662-5664.
23. Gulnik, S. V., L. I. Suvorov, B. Liu, B. Yu, B. Anderson, H. Mitsuya, and J. W. Erickson. 1995. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 34: 9282-9287.
24. Haertle, T., C. J. Carrera, D. B. Wasson, L. C. Sowers, D. D. Richman, and D. A. Carson. 1988. Metabolism and anti-human immunodeficiency virus-1 activity of 2-halo-2′,3′-dideoxyadenosine derivatives. J. Biol. Chem. 263: 5870-5875.
25. Harada, S., Y. Koyanagi, and N. Yamamoto. 1985. Infection of HTLV-III/ LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science 229:563-566.
26. Harrigan, P. R., S. Bloor, and B. A. Larder. 1998. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro. J. Virol. 72:3773-3778.
27. Harrigan, P. R., I. Kinghorn, S. Bloor, S. D. Kemp, I. Najera, A. Kohli, and B. A. Larder. 1996. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility. J. Virol. 70:5930-5934.
28. Ho, D. D., T. Toyoshima, H. Mo, D. J. Kempf, D. Norbeck, C.-M. Chen, N. E. Wideburg, S. K. Burt, J. W. Erickson, and M. K. Singh. 1994. Characterization of HIV-1 variants with increased resistance to a C2-symmetric protease inhibitor. J. Virol. 68:2016-2020.
29. Jacobsen, H., M. Hänggi, M. Ott, I. B. Duncan, S. Owen, M. Andreoni, S. Vella, and J. Mous. 1996. In vivo resistance to a HIV-1 proteinase inhibitor: mutations, kinetics, and frequencies. J. Infect. Dis. 173:1379-1387.
30. Japour, A. J., D. L. Mayers, V. A. Johnson, D. R. Kuritzkes, L. A. Beckett, J. M. Arduino, J. Lane, R. J. Black, P. S. Reichelderfer, R. T. D'Aquila, et al. 1993. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group. Antimicrob. Agents Chemother. 37:1095-1101.
31. Kozal, M. J., N. Shah, N. Shen, R. Yang, R. Fucini, T. C. Merigan, D. D. Richman, D. Morris, E. Hubbell, M. Chee, and T. R. Gingeras. 1996. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat. Med. 2:753-759.
32. Larder, B. A., S. D. Kemp, and P. R. Harrigan. 1995. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269:696-699.
33. Lech, W. J., G. Wang, Y. L. Yang, Y. Chee, K. Dorman, D. McCrae, L. C. Lazzeroni, J. W. Erickson, J. S. Sinsheimer, and A. H. Kaplan. 1996. In vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects. J. Virol. 70:2038-2043.
34. Loeb, D. D., R. Swanstrom, L. Everitt, M. Manchester, S. E. Stamper, and C. A. Hutchison. 1989. Complete mutagenesis of the HIV-1 protease. Nature 340:397-400.
35. Maeda, Y., D. J. Venzon, and H. Mitsuya. 1998. Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance. J. Infect. Dis. 177: 1207-1213.
36. Markowitz, M., H. Mo, D. J. Kempf, D. W. Norbeck, T. N. Bhat, J. W. Erickson, and D. D. Ho. 1995. Selection and analysis of HIV-1 variants with increased resistance to ABT-538, a novel protease inhibitor. J. Virol. 69:701-706.
37. Martinez-Picado, J., L. Sutton, A. H. Helfant, A. Savara, and R. T. D'Aquila. 1997. Novel clonal analyses of resistance to HIV-1 RT and protease inhibitors, abstr. 45. In Abstracts of the International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication.
38. Maschera, B., G. Darby, G. Palu, L. L. Wright, M. Tisdale, R. Myers, E. D. Blair, and E. S. Furfine. 1996. Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex. J. Biol. Chem. 271: 33231-33235.
39. Maschera, B., E. Furfine, and E. D. Blair. 1995. Analysis of resistance to HIV-1 protease inhibitors by using matched bacterial expression and proviral infection vectors. J. Virol. 69:5431-5436.
40. Meyerhans, A., J. P. Vartanian, and S. Wain-Hobson. 1990. DNA recombination during PCR. Nucleic Acids Res. 18:1687-1691.
41. Molla, A., M. Korneyeva, Q. Gao, S. Vasavanonda, P. J. Schipper, H.-M. Mo, M. Markowitz, T. Chernyavskiy, P. Niu, N. Lyons, A. Hsu, G. R. Granneman, D. D. Ho, C. A. B. Boucher, J. M. Leonard, D. W. Norbeck, and D. J. Kempf. 1996. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 2:760-766.
42. Nagylaki, T. 1992. Introduction to theoretical population genetics, p. 25-27. Springer-Verlag KG, Berlin, Germany.
43. Nijhuis, M., R. Schuurman, D. de Jong, P. Schipper, S. Danner, and C. Boucher. 1997. Selection of HIV-1 variants with increased fitness during ritonavir therapy, abstr. 92. In Abstracts of the International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication.
44. Para, M. F., R. Coombs, A. Collier, D. Glidden, R. Bassett, F. Duff, C. Boucher, R. Leavitt, J. Condra, C. Pettinelli, and the ACTG 333 Study Team. 1998. Relationship of baseline genotype to RNA response in ACTG 333 after switching from long term saquinavir to indinavir or saquinavir soft gel capsule, abstr. 511. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections.
45. Patick, A. K., M. Duran, Y. Cao, T. Ho, A. Pei, M. R. Keller, J. Peterkin, S. Chapman, B. Anderson, D. Ho, and M. Markowitz. 1996. Genotypic and phenotypic characterization of HIV-1 variants isolated from in vitro selection studies and from patients treated with the protease inhibitor, nelfinavir, ahstr. 29. In Abstracts of the 5th International Workshop on HIV Drug Resistance.
46. Patick, A. K., M. Duran, Y. Cao, D. Shugarts, M. R. Keller, E. Mazabel, M. Knowles, S. Chapman, D. R. Kuritzkes, and M. Markowitz. 1998. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob. Agents Chemother. 42:2637-2644.
47. Patick, A. K., D. Kuritzkes, V. A. Johnson, D. Shugarts, M. Bakhtiari, K. E. Potts, A. Farnsworth, R. Anderson, J. L. Koel, J. D. Hazelwood, C. D. Nail, M. Duran, M. Markowitz, D. Ho, and D. Richman. 1997. Genotypic and phenotypic analyses of HIV-1 variants isolated from patients treated with nelfinavir and other HIV-1 protease inhibitors, abstr. 18. In Abstracts of the International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication.
48. Patick, A. K., H. Mo, M. Markowitz, K. Appelt, B. Wu, L. Musick, V. Kalish, S. Kaldor, S. Reich, D. Ho, and S. Webber. 1996. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob. Agents Chemother. 40:292-297.
49. Patick, A. K., R. Rose, J. Greytok, C. M. Bechtold, M. A. Hermsmeier, P. T. Chen, J. C. Barrish, R. Zahler, R. J. Colonno, and P. F. Lin. 1995. Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor. J. Virol. 69:2148-2152.
50. Paul, M., K. Logue, and L. T. Bacheler. 1997, Fitness of protease inhibitor resistant viruses, abstr. 119. In Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections.
51. Pazhanisamy, S., C. M. Stuver, A. B. Cullinan, N. Margolin, B. G. Rao, and D. J. Livingston. 1996. Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants. J. Biol. Chem. 271:17979-17985.
52. Perelson, A. S., A. U. Neumann, M. Markowitz, J. M. Leonard, and D. D. Ho. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582-1586.
53. Rashtchian, A., D. M. Buchman, D. M. Schuster, and M. S. Beringer. 1992. Uracil DNA glycosilase-mediated cloning of PCR-amplified DNA: application to genomic and cDNA cloning. Anal. Biochem. 206:91-97.
54. Rashtchian, A., C. G. Thorton, and G. Heidecker. 1992. A novel method for site-directed mutagenesis using PCR and uracil DNA glycosylase. PCR Methods Appl. 2:124.
55. Rose, R. E., Y.-F. Gong, J. A. Greytok, C. M. Bechtold, B. J. Teryy, B. S. Robinson, M. Alam. R. J. Colonno, and P.-F. Lin. 1996. HIV-1 viral background plays a major role in development of resistance to protease inhibitors. Proc. Natl. Acad. Sci. USA 93:1648-1653.
56. Schock, H. B., V. M. Garsky, and L. C. Kuo. 1996. Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. J. Biol. Chem. 271:31957-31963.
57. Sharma, P. L., and C. S. Crumpacker. 1997. Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation. J. Virol. 71:8846-8851.
58. Tebas, P., E. Kane, M. Klebert, J. Simpson, W. G. Powderly, and K. Henry. 1998. Virologic responses to a ritonavir/saquinavir containing regimen in patients who have previously failed nelfinavir, abstr. 510. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections.
59. Zennou, V., F. Mammano, S. Paulous, D. Mathez, and F. Clavel. 1998. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J. Virol. 72:3300-3306.
60. Zhang, D., A. M. Caliendo, J. J. Eron, K. M. DeVore, J. C. Kaplan, M. S. Hirsch, and R. T. D'Aquila. 1994. Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 38:282-287.
61. Zhang, Y.-M., H. Imamichi, T. Imamichi, H. C. Lane, J. Falloon, M. B. Vasudevachari, and N. P. Salzman. 1997. Drug resistance during indinavir therapy is caused by mutations in the protease gene and its gag substrate cleavage sites. J. Virol. 71:6662-6670.
62. Zolopa, A. R., R. W. Shafer, A. Warford, J. G. Montoya, D. Katzenstein, and T. C. Merigan. 1998. Predictors of antiviral response to saquinavir/ritonavir therapy in a clinical cohort who failed prior protease inhibitors: a comparison of clinical characteristics, antiretroviral drug history and HIV genotype, abstr. 54. In Abstracts of the 2nd International Workshop on Drug Resistance and Treatment Strategies.